Shrestha and Shannon Write for Law360 on Skinny Label Ruling

Taft Pharmaceutical and Life Science Litigation attorneys Roshan Shrestha, Ph.D. and Luke Shannon wrote in Law360 on the U.S. Court of Appeals for the Federal Circuit's June 25 opinion in Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc.

Read the article here.

Shrestha focuses his practice on all aspects of intellectual property law, including patent litigation, prosecution, and opinion work in the chemical, pharmaceutical, and electronic material arts. He has a broad scope of pharmaceutical and life sciences capabilities, including Hatch-Waxman litigation and inner parts review proceedings at the USPTO. Shrestha has been recognized by Super Lawyers and Leading Lawyers Network and was named to Law Bulletin's "40 Illinois Attorneys Under 40 to Watch."

Shannon focuses on patent infringement suits arising under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act, and other disputes involving pharmaceutical and life sciences and other intellectual property issues. He also advises clients regarding post-grant procedures, including inter partes review proceedings, and has experience preparing Paragraph IV notice letters, as well as non-infringement and invalidity opinions.